Related Experiment Video
Updated: Jul 31, 2026
Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
Published on: May 5, 2021
Precision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient Tumor-Derived
Yicheng Wang1,2,3, Haotian Chen1,3, Zhijin Zhang1,3
1Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
Abstract:
When a patient has two or more primary tumors, excluding the possibility of diffuse, recurrent, or metastatic, they can be defined as having multiple primary malignant neoplasms (MPMNs). Moreover, cases of three primary urinary tract tumors are very rare. Here, we reported a patient of MPMNs with four primary tumors, including three urinary tract cancers (renal cancer, prostate cancer, and bladder cancer) and lung cancer. The four tumors appeared over 13 years, and pathological results confirmed that they were all primary tumors after different surgeries. In addition, we established patient-derived organoids (PDOs) by collecting tumor specimens. Hematoxylin-eosin (H&E) staining of PDOs showed that the organoids were histopathological consistent with parental tumor. Immunohistochemistry showed that PDOs can also reflect the expression of pathological markers in patients. At the same time, PDOs may also serve as "avatars" of patients to predict sensitivity to different drugs. In summary, we reported a case of MPMNs with four primary tumors and established PDOs from its tumor specimens. A personalized treatment strategy was established based on the histopathological characteristics of the organoids.
Insights
This study reports a rare case of multiple primary malignant neoplasms (MPMNs) involving four distinct cancers. Patient-derived organoids were established to guide personalized treatment strategies for these complex cases.
Area of Science:
- Oncology
- Cancer Research
- Urology
Background:
- Multiple primary malignant neoplasms (MPMNs) are defined as two or more distinct primary tumors.
- Cases with three primary urinary tract tumors are exceptionally rare.
- This report details an unprecedented case of MPMNs with four primary tumors.
Purpose of the Study:
- To document a rare case of MPMNs with four primary tumors, including three in the urinary tract and one lung cancer.
- To establish patient-derived organoids (PDOs) from tumor specimens.
- To explore the utility of PDOs in reflecting tumor characteristics and predicting drug sensitivity for personalized treatment.
Main Methods:
- Pathological confirmation of four distinct primary tumors over 13 years.
- Establishment of patient-derived organoids (PDOs) from tumor specimens.
- Histopathological and immunohistochemical analysis of PDOs to assess consistency with parental tumors and marker expression.
Main Results:
- Confirmation of four primary tumors: renal cancer, prostate cancer, bladder cancer, and lung cancer.
- PDOs successfully recapitulated the histopathological features and marker expression of the primary tumors.
- PDOs demonstrated potential as patient 'avatars' for predicting drug sensitivity.
Conclusions:
- A rare case of MPMNs with four primary tumors was successfully managed.
- Patient-derived organoids serve as valuable tools for understanding tumor biology and guiding personalized therapy.
- PDOs offer a promising avenue for developing tailored treatment strategies in complex oncological cases.
